Zhengwei Huang

Dr. Zhengwei Huang

Jinan University, Guangzhou, Guangdong, China

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2024 in Medcomm
Verified
Journal Article
Open access
WZWanchen Zhao
Wanchen Zhao
LWLiqing Wang
Liqing Wang
MZMeihong Zhang
Meihong Zhang
ZLZhiqi Liu
Zhiqi Liu
CWChuanbin Wu
Chuanbin Wu
GQGuilan Quan
Guilan Quan
Photodynamic therapy (PDT) is a temporally and spatially precisely controllable, noninvasive, and potentially highly efficient method of phototherapy. The three components of PDT primarily include photosensitizers, oxygen, and light. PDT employs specific wavelengths of light to active photosensitizers at the tumor site, generating reactive oxygen species that are fatal to tumor cells. Nevertheless, traditional photosensitizers have disadvantages such as poor water solubility, severe oxygen‐dependency, and low targetability, and the light is difficult to penetrate the deep tumor tissue, which remains the toughest task in the application of PDT in the clinic. Here, we systematically summarize the development and the molecular mechanisms of photosensitizers, and the challenges of PDT in tumor management, highlighting the advantages of nanocarriers‐based PDT against cancer. The development of third generation photosensitizers has opened up new horizons in PDT, and the cooperation between nanocarriers and PDT has attained satisfactory achievements. Finally, the clinical studies of PDT are discussed. Overall, we present an overview and our perspective of PDT in the field of tumor management, and we believe this work will provide a new insight into tumor‐based PDT.

8 March 2023 in ACS Nano
Verified
Journal Article
Closed access
FFFangqin Fu
Fangqin Fu
WWWenhao Wang
Wenhao Wang
LWLinjing Wu
Linjing Wu
WWWenhua Wang
Wenhua Wang
Zhengwei HuangZhengwei Huang
Zhengwei Huang
XPXin Pan
Xin Pan

1 April 2021 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
WWWenhao Wang
Wenhao Wang
Zhengwei HuangZhengwei Huang
Zhengwei Huang
YLYanbei Li
Yanbei Li
WWWenhua Wang
Wenhua Wang
JSJiayu Shi
Jiayu Shi
Chuanbin WuChuanbin Wu
Chuanbin Wu
When nanoparticles were introduced into the biological media, the protein corona would be formed, which endowed the nanoparticles with new bio-identities. Thus, controlling protein corona formation is critical to in vivo therapeutic effect. Controlling the particle size is the most feasible method during design, and the influence of media pH which varies with disease condition is quite important. The impact of particle size and pH on bovine serum albumin (BSA) corona formation of solid lipid nanoparticles (SLNs) was studied here. The BSA corona formation of SLNs with increasing particle size (120–480 nm) in pH 6.0 and 7.4 was investigated. Multiple techniques were employed for visualization study, conformational structure study and mechanism study, etc. “BSA corona-caused aggregation” of SLN2‒3 was revealed in pH 6.0 while the dispersed state of SLNs was maintained in pH 7.4, which significantly affected the secondary structure of BSA and cell uptake of SLNs. The main interaction was driven by van der Waals force plus hydrogen bonding in pH 7.4, while by electrostatic attraction in pH 6.0, and size-dependent adsorption was confirmed. This study provides a systematic insight to the understanding of protein corona formation of SLNs.

22 April 2022 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
Wenhao WangWenhao Wang
Wenhao Wang
Zhengwei HuangZhengwei Huang
Zhengwei Huang
Ying HuangYing Huang
Ying Huang
XZXuejuan Zhang
Xuejuan Zhang
JHJiayuan Huang
Jiayuan Huang
XPXin Pan
Xin Pan

18 September 2020 in Drug Delivery and Translational Research
Verified
Journal Article
Closed access
PDF file
CMCheng Ma
Cheng Ma
MWMingjun Wu
Mingjun Wu
WYWeifen Ye
Weifen Ye
Zhengwei HuangZhengwei Huang
Zhengwei Huang
XMXiangyu Ma
Xiangyu Ma
CWChuanbin Wu
Chuanbin Wu

24 January 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
SPSiyuan Peng
Siyuan Peng
Wenhao WangWenhao Wang
Wenhao Wang
RZRui Zhang
Rui Zhang
Chuanbin WuChuanbin Wu
Chuanbin Wu
XPXin Pan
Xin Pan
Zhengwei HuangZhengwei Huang
Zhengwei Huang
With the development of nanotechnology and confronting the problems of traditional pharmaceutical formulations in treating lung diseases, inhalable nano-formulations have attracted interest. Inhalable nano-formulations for treating lung diseases allow for precise pulmonary drug delivery, overcoming physiological barriers, improving aerosol lung deposition rates, and increasing drug bioavailability. They are expected to solve the difficulties faced in treating lung diseases. However, limited success has been recorded in the industrialization translation of inhalable nano-formulations. Only one relevant product has been approved by the FDA to date, suggesting that there are still many issues to be resolved in the clinical application of inhalable nano-formulations. These systems are characterized by a dependence on inhalation devices, while the adaptability of device formulation is still inconclusive, which is the most important issue impeding translational research. In this review, we categorized various inhalable nano-formulations, summarized the advantages of inhalable nano-formulations over conventional inhalation formulations, and listed the inhalable nano-formulations undergoing clinical studies. We focused on the influence of inhalation devices on nano-formulations and analyzed their adaptability. After extensive analysis of the drug delivery mechanisms, technical processes, and limitations of different inhalation devices, we concluded that vibrating mesh nebulizers might be most suitable for delivering inhalable nano-formulations, and related examples were introduced to validate our view. Finally, we presented the challenges and outlook for future development. We anticipate providing an informative reference for the field.